Zydus Lifesciences Limited on Monday said it received final approval from the health regulator of the United States for Deflazacort oral suspension used for treating a severe form of muscular dystrophy.

The approval given by United States Food and Drug Administration (USFDA) is for Deflazacort oral suspension of 22.75mg/ml, the company stated in a regulatory filing with the stock exchanges. Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy (DMD) in patients five years of age and older, the company added.

Deflazacort belongs to a group of medications called steroids. It works by decreasing inflammation and slowing down an overactive immune system. Deflazacort oral suspension will be produced at Doppel, Italy, the company stated. The group now has 424 app

See Full Page